Immune cell therapy takes on stubborn stomach bug in transplant patients

NCT ID NCT04691622

Recruiting now Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether specially grown immune cells (norovirus-specific T-cells) can safely treat chronic norovirus infections in people with weakened immune systems, such as those who had a stem cell or organ transplant. The study will enroll 48 participants and give them one of three doses of these cells. The main goal is to check for side effects, not yet to see if the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: norovirus-specific T-cells (NST therapy)
What this could lead to: If it works, this could point toward a treatment for chronic norovirus in people with weakened immune systems, helping clear the infection.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (48 people) and may not work or could cause side effects like graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC NOROVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inborn error of immunity norovirus infectious disease Primary Immunodeficiency Diseases viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PRIMARY IMMUNODEFICIENCY DISORDERS (PID) VIRAL INFECTION

Contacts and locations

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
National Institutes of Health (NIH)
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.